- Associated Press - Friday, January 14, 2011

LIVER RISK: The Food and Drug Administration is adding new warnings to the label of Sanofi-Aventis’ drug Multaq after several reports of liver damage by patients taking the drug.

HEART RHYTHMS: Multaq was approved in July 2009 to treat atrial flutter and atrial fibrillation which are irregular heart rhythms that can reduce blood flow and lead to stroke.

SALES UNAFFECTED: Leerink Swann analyst Seamus Fernandez said the safety warning is unlikely to hurt U.S. sales of Multaq, which he estimates at $128 million for 2010.

LOAD COMMENTS ()

 

Click to Read More

Click to Hide